| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/19/2005 | CN1565630A Novel pestilence DNA vaccine and its construction and application |
| 01/19/2005 | CN1565629A Novel pestilence DNA vaccine and its usage |
| 01/19/2005 | CN1565627A Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation |
| 01/19/2005 | CN1185012C DNA vaccine pVFS of SARS virus |
| 01/19/2005 | CN1185011C DNA vaccine pVPS of SARS virus |
| 01/19/2005 | CN1184961C Use of EGF-R antagonists in preparing drug |
| 01/18/2005 | US6844422 Inhibitor protein of the wnt signal pathway |
| 01/18/2005 | US6844327 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/18/2005 | US6844326 Treatment of alopecia |
| 01/18/2005 | US6844324 Having membrane fusion component comprising antennapedia binding domain motif or functional equivalent; lysine and aspartic acid attachment of each component; can accomodate large DNA molecules |
| 01/18/2005 | US6844191 Osteogenic cell growth using a TGFβ1-von Willebrand's factor fusion protein |
| 01/18/2005 | US6844189 Chromosome 17P-linked prostate cancer susceptibility gene |
| 01/18/2005 | US6844175 Methods of inhibition using glycosyl sulfotransferase-3 |
| 01/18/2005 | US6844153 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/18/2005 | US6844011 Methods for inhibiting rejection of transplanted tissue |
| 01/18/2005 | US6844001 Adjuvants and copolymer compositions |
| 01/18/2005 | US6844000 A purified Parapoxvirus ovis envelope protein termed "B2L" can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response |
| 01/18/2005 | US6843991 Use of the M3 protein of MHV68 to block binding of a chemokine to its receptor |
| 01/13/2005 | WO2005003323A2 Use of calcium binding proteins to improve cardiac contractile function |
| 01/13/2005 | WO2005003295A2 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | WO2005003158A2 Compositions and methods for increasing bone mineralization |
| 01/13/2005 | WO2005002607A2 Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
| 01/13/2005 | WO2005002601A1 Conditioned matrix compositions for tissue restoration |
| 01/13/2005 | WO2005002573A2 Methods for using modulators of proline-rich tyrosine kinase 2 |
| 01/13/2005 | WO2005002527A2 Sirt1 modulation of adipogenesis and adipose function |
| 01/13/2005 | WO2005002507A2 Modulation of survivin expression |
| 01/13/2005 | WO2005002504A2 Protection against vertical transmission of pathogenic infections |
| 01/13/2005 | WO2004099422A3 Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes |
| 01/13/2005 | WO2004094605A8 Methods and compositions for inhibiting stat signaling pathways |
| 01/13/2005 | WO2004082567A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 01/13/2005 | WO2004069876A3 Trimeric polypeptide construct to induce an enduring t cell response |
| 01/13/2005 | WO2004055167A3 Alphavirus particles and methods for preparation |
| 01/13/2005 | WO2004044135A3 Structural motifs and oligomeric compounds and their use in gene modulation |
| 01/13/2005 | WO2004044131A3 Cross-linked oligomeric compounds and their use in gene modulation |
| 01/13/2005 | WO2004042077A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | WO2003072715A8 Gasp1: a follistatin domain containing protein |
| 01/13/2005 | WO2003017943A3 Therapeutic compositions and methods for treating viral infection |
| 01/13/2005 | US20050009856 Administering a compound which inhibits selectively mu opioid receptor activity or activation to treat conditions including Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease, and dyskinesias arising as a side-effect of a therapeutic agent. |
| 01/13/2005 | US20050009773 Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
| 01/13/2005 | US20050009772 Methods and compositions for the treatment of glaucoma and other retinal diseases |
| 01/13/2005 | US20050009771 Methods and systems for identifying naturally occurring antisense transcripts and methods, kits and arrays utilizing same |
| 01/13/2005 | US20050009770 Use of excipients to increase DNA uptake by swine muscle cells |
| 01/13/2005 | US20050009738 Interleukin with nucleic acid carrier |
| 01/13/2005 | US20050009186 Expression vector comprising 3' and 5' long terminal repeats and preferential splice junctions for use as heterologous gene transfer tool; gene therapy |
| 01/13/2005 | US20050009184 Humanised baculovirus |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009141 Epidermal differentiation factor |
| 01/13/2005 | US20050009107 Using hybridoma cells to generate monoclonal antibody specific to 7-transmembrane receptor protein for use in the diagnosis, prevention and treatment of psychological and nervous system disorders |
| 01/13/2005 | US20050009085 44 Human secreted proteins |
| 01/13/2005 | US20050009073 Polyamide nucleic acid derivatives, and agents, and processes for preparing them |
| 01/13/2005 | US20050009042 Oligonucleotide seqences for controlling expression of leptin receptor gene associated protein (OB-RGRP); for treatment and prevention of bone, thrombic, sexual, blood, immunological, inflammatory and cancer disorders |
| 01/13/2005 | US20050009025 A soluble T cell receptor for use as diagnostic indicator of infection and autoimmune diseases |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008689 High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| 01/13/2005 | US20050008661 Mixture of polymer in solvent; drug delivery; storage stability |
| 01/13/2005 | US20050008651 Modulating replication via immunogen and pharmaceutically or veterinarily acceptable vehicles |
| 01/13/2005 | US20050008643 Diagnostic methods and agents |
| 01/13/2005 | US20050008628 Polynucleotide gene expression construction; therapy of diseases caused by damage to excitable tissue; cardiovascular disorders therapy; antidiabetic agents; Parkinson's disease; antiepileptic agents; neurodegenerative agents |
| 01/13/2005 | US20050008625 Antibody affinity engineering by serial epitope-guided complementarity replacement |
| 01/13/2005 | US20050008623 In vitro production of dendritic cells from CD14+ monocytes |
| 01/13/2005 | US20050008618 Composition for delivering an agent to a target cell and uses thereof |
| 01/13/2005 | US20050008617 Compositions and methods for delivery of short interfering RNA and short hairpin RNA |
| 01/13/2005 | CA2568859A1 Cytokine variant polypeptides |
| 01/13/2005 | CA2563362A1 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 01/13/2005 | CA2530490A1 Conditioned matrix compositions for tissue restoration |
| 01/13/2005 | CA2529578A1 Antibodies for use in increasing bone mineralization |
| 01/13/2005 | CA2529058A1 Increased t-cell tumor infiltration by mutant light |
| 01/13/2005 | CA2528084A1 Sppls as modifiers of the p53 pathway and methods of use |
| 01/13/2005 | CA2527908A1 Mylks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2527905A1 Nadks as modifiers of branching morphogenesis and methods of use |
| 01/13/2005 | CA2524495A1 Modulation of survivin expression |
| 01/12/2005 | EP1496116A1 Anticancer agents using vero toxin variants |
| 01/12/2005 | EP1495141A2 Hiv therapeutic |
| 01/12/2005 | EP1495130A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/12/2005 | EP1495123A1 Erbb3 based methods and compositions for treating neoplasms |
| 01/12/2005 | EP1495122A1 Antiviral therapy on the basis of rna interference |
| 01/12/2005 | EP1495120A2 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/12/2005 | EP1495117A2 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 01/12/2005 | EP1495113A2 Stimulation of nerve cell regeneration |
| 01/12/2005 | EP1495110A1 Recombinant spores |
| 01/12/2005 | EP1494752A1 Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| 01/12/2005 | EP1494722A1 Treatment methods for eotaxin mediated inflammatory conditions |
| 01/12/2005 | EP1494705A1 A composition and method for killing of tumours |
| 01/12/2005 | EP1494670A1 Medicine for treating cancer |
| 01/12/2005 | EP1494613A2 Potent oncolytic herpes simplex virus for cancer therapy |
| 01/12/2005 | EP1443970A4 Promoters exhibiting endothelial cell specificity and methods of using same |
| 01/12/2005 | EP1414500A4 Akt and regulation of ra synovial fibroblast apoptosis |
| 01/12/2005 | EP1194122B1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/12/2005 | EP1183228B1 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds. |
| 01/12/2005 | EP1002082B1 Transcriptional silencer protein nrf |
| 01/12/2005 | EP0996460B1 Treatment of kidney fibrosis with antibodies against integrin alpha-v-beta 6 |
| 01/12/2005 | CN1564829A Antibodies to insulin-like growth factor I receptor |
| 01/12/2005 | CN1564828A Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/12/2005 | CN1564826A Human G-protein chemokine receptor (CCR5) HDGNR10 |
| 01/12/2005 | CN1564696A Compositions for and methods of treating and preventing sirs/sepsis |
| 01/12/2005 | CN1563401A RNA adaptor capable of restraining bacillus typhosus from invading to cells of human body, and preparation method |
| 01/12/2005 | CN1563390A Common expression vector between 2 subtype receptor of human somatotropin release in hibiting factor and cytosine deaminease of colibacillus, establishment and application |
| 01/12/2005 | CN1563382A Gene of Chinese Mainland SJPP gene stock of japanese blood fluke, clone, expression and application |
| 01/12/2005 | CN1562375A Combination of medication produced from attenuated salmonella bacteria possessing effect of radiation protection and anti tumour |